CoChat

Deacetylation induced nuclear condensation of HP1γ promotes multiple myeloma drug resistance

Open access

The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.

Abstract

Acquired chemoresistance to proteasome inhibitors is a major obstacle in managing multiple myeloma but key regulators and underlying mechanisms still remain to be explored. We find that high level of HP1γ is associated with low acetylation modification in the bortezomib-resistant myeloma cells using SILAC-based acetyl-proteomics assay, and higher HP1γ level is positively correlated with poorer outcomes in the clinic. Mechanistically, elevated HDAC1 in the bortezomib-resistant myeloma cells deacetylates HP1γ at lysine 5 and consequently alleviates the ubiquitin-mediated protein degradation, as well as the aberrant DNA repair capacity. HP1γ interacts with the MDC1 to induce DNA repair, and simultaneously the deacetylation modification and the interaction with MDC1 enhance the nuclear condensation of HP1γ protein and the chromatin accessibility of its target genes governing sensitivity to proteasome inhibitors, such as CD40, FOS and JUN. Thus, targeting HP1γ stability by using HDAC1 inhibitor re-sensitizes bortezomib-resistant myeloma cells to proteasome inhibitors treatment in vitro and in vivo. Our findings elucidate a previously unrecognized role of HP1γ in inducing drug resistance to proteasome inhibitors of myeloma cells and suggest that targeting HP1γ may be efficacious for overcoming drug resistance in refractory or relapsed multiple myeloma patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-023-37013-x

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 HP1γ and its acetylation modification are associated with BTZ resistance in MM cells. a Schematic illustration of the manipulation of SILAC assay in the BR and WT MM.1 S cells. b Shown were 176 differential expressed proteins including 48 downregulated and 128 upregulated proteins (cutoff, 1.5 folds), furthermore, 167 proteins whose acetylation level were changed involving 50 downregulation and 117 upregulation (cutoff, 1.5 folds) in the BR MM.1 S cells compared to the WT cells detected by SILAC assay. c Venn diagram showed the most prominent change of protein-HP1γ in proteomics and acetylated omics of WT and BR MM cells. d Analysis of acetylated peptides identified specific acetylation motifs associated with lysine acetylation. e Relative b2+ intensity for K5 acetylation in WT and BR MM cells by mass spectrum (mean ± s.d.; n = 1). f Western blots showed the protein and acetylation levels of HP1γ in BR and WT MM cells. g Co-immunoprecipitation (Co-IP) assay showed the protein and acetylation levels of HP1γ in BR and WT MM cells with HP1γ-flag stably overexpression. Input, 2% lysate. IP, M2-flag antibody. h Correlation of CBX3 (HP1γ) expression with overall survival (OS) in 586 patients after receiving BTZ-based treatment regimens from the coMMpass cohort. i Expression of CBX3 in patients acquired with complete response (CR) (n = 114) and partial response (PR) (n = 125) in coMMpass cohort, and (j) in MM patients with responses (R, n = 84) and without response (non-R, n = 125) to BTZ-based regimens in the cohort GSE2658. 200037 and 201097, two probes in gene array. k Representative immunohistochemical staining of HP1γ protein in specimen from two patients acquired complete response (CR) or disease progression (DP) after treatment. l Alteration of IC50 to BTZ treatment in the NT Ctrl and HP1γ KD cells (n = 3). m Quantification of the percentage of apoptotic cells in the Vector with HP1γ OE cells and NT Ctrl with HP1γ KD cells induced by 10 nM BTZ for 24 h by flow cytometry assay and analyzes the difference between two groups for n = 4 independent experiments (mean ± s.d.). P values were determined by Pearson’s coefficient and log-rank test (h) and Student’s t test (i, j, m). Source data are provided as a Source data file.
Fig. 1 HP1γ and its acetylation modification are associated with BTZ resistance in MM cells. a Schematic illustration of the manipulation of SILAC assay in the BR and WT MM.1 S cells. b Shown were 176 differential expressed proteins including 48 downregulated and 128 upregulated proteins (cutoff, 1.5 folds), furthermore, 167 proteins whose acetylation level were changed involving 50 downregulation and 117 upregulation (cutoff, 1.5 folds) in the BR MM.1 S cells compared to the WT cells detected by SILAC assay. c Venn diagram showed the most prominent change of protein-HP1γ in proteomics and acetylated omics of WT and BR MM cells. d Analysis of acetylated peptides identified specific acetylation motifs associated with lysine acetylation. e Relative b2+ intensity for K5 acetylation in WT and BR MM cells by mass spectrum (mean ± s.d.; n = 1). f Western blots showed the protein and acetylation levels of HP1γ in BR and WT MM cells. g Co-immunoprecipitation (Co-IP) assay showed the protein and acetylation levels of HP1γ in BR and WT MM cells with HP1γ-flag stably overexpression. Input, 2% lysate. IP, M2-flag antibody. h Correlation of CBX3 (HP1γ) expression with overall survival (OS) in 586 patients after receiving BTZ-based treatment regimens from the coMMpass cohort. i Expression of CBX3 in patients acquired with complete response (CR) (n = 114) and partial response (PR) (n = 125) in coMMpass cohort, and (j) in MM patients with responses (R, n = 84) and without response (non-R, n = 125) to BTZ-based regimens in the cohort GSE2658. 200037 and 201097, two probes in gene array. k Representative immunohistochemical staining of HP1γ protein in specimen from two patients acquired complete response (CR) or disease progression (DP) after treatment. l Alteration of IC50 to BTZ treatment in the NT Ctrl and HP1γ KD cells (n = 3). m Quantification of the percentage of apoptotic cells in the Vector with HP1γ OE cells and NT Ctrl with HP1γ KD cells induced by 10 nM BTZ for 24 h by flow cytometry assay and analyzes the difference between two groups for n = 4 independent experiments (mean ± s.d.). P values were determined by Pearson’s coefficient and log-rank test (h) and Student’s t test (i, j, m). Source data are provided as a Source data file.CC BY · PubMed Central
Fig. 2 HDAC1 deacetylates and stabilizes HP1γ protein. a Silver staining for flag-pulldown of flag-HP1γ complex in HEK293T cells. b Co-IP assay to show interactions between endogenous HP1γ with HDAC1 and (c) endogenous HDAC1 with HP1γ in MM.1 S cells. Input, 2% whole cell lysate. d Coomassie blue staining to show in vitro expression of GST-fusion HP1γ protein and in vivo expression of flag-HDAC1 protein in HEK293T. e GST-pulldown assays to show the interaction between purified HDAC1-flag and GST-tagged-HP1γ protein in vitro. Input, purified HDAC1-flag. f Levels of HP1γ protein in HEK293T cells with increasing overexpression of HDAC1 by western blotting. g Western blotting shows the alteration of HP1γ, HDAC1 and HDAC2 levels in WT and BR MM.1 S and LP-1 cells. h Silver staining for flag-pulldown in the WT and BR LP-1 cells infected with lentivirus carrying HP1γ-flag for 72 h. i Alteration of interaction between HP1γ and HDAC1 in WT and BR LP-1 and MM.1 S cells infected with HP1γ-flag for 72 h. Input, 2% lysate. j Degradation rate of HP1γ protein in WT and BR MM.1 S and LP-1 cells treated with 20 μM cycloheximide (CHX). k Western blotting shows the HP1γ protein level in the HEK293T cells transfected with flag-tagged HP1γ WT, K5R and K5Q. l Ubiquitination status of HP1γ-WT-flag, HP1γ-K5R-flag or HP1γ-K5Q-flag in HEK293T cells. m Polyubiquitination linkage features of HP1γ-flag mapping by positive mutations of ubiquitin in HEK293T cells. n K11-linked polyubiquitination of HP1γ-flag in HEK293T cells. Source data are provided as a Source data file.
Fig. 2 HDAC1 deacetylates and stabilizes HP1γ protein. a Silver staining for flag-pulldown of flag-HP1γ complex in HEK293T cells. b Co-IP assay to show interactions between endogenous HP1γ with HDAC1 and (c) endogenous HDAC1 with HP1γ in MM.1 S cells. Input, 2% whole cell lysate. d Coomassie blue staining to show in vitro expression of GST-fusion HP1γ protein and in vivo expression of flag-HDAC1 protein in HEK293T. e GST-pulldown assays to show the interaction between purified HDAC1-flag and GST-tagged-HP1γ protein in vitro. Input, purified HDAC1-flag. f Levels of HP1γ protein in HEK293T cells with increasing overexpression of HDAC1 by western blotting. g Western blotting shows the alteration of HP1γ, HDAC1 and HDAC2 levels in WT and BR MM.1 S and LP-1 cells. h Silver staining for flag-pulldown in the WT and BR LP-1 cells infected with lentivirus carrying HP1γ-flag for 72 h. i Alteration of interaction between HP1γ and HDAC1 in WT and BR LP-1 and MM.1 S cells infected with HP1γ-flag for 72 h. Input, 2% lysate. j Degradation rate of HP1γ protein in WT and BR MM.1 S and LP-1 cells treated with 20 μM cycloheximide (CHX). k Western blotting shows the HP1γ protein level in the HEK293T cells transfected with flag-tagged HP1γ WT, K5R and K5Q. l Ubiquitination status of HP1γ-WT-flag, HP1γ-K5R-flag or HP1γ-K5Q-flag in HEK293T cells. m Polyubiquitination linkage features of HP1γ-flag mapping by positive mutations of ubiquitin in HEK293T cells. n K11-linked polyubiquitination of HP1γ-flag in HEK293T cells. Source data are provided as a Source data file.CC BY · PubMed Central
Fig. 3 HP1γ facilitates homologous recombination of DNA repair. a Western blotting shows γH2AX and cleaved PARP in WT and BR MM cell treated with BTZ for 24 h. b Levels of γH2AX in WT and BR MM cells treated with camptothecin (CPT, 0–4 μM) for 24 h. c Western blotting shows γH2AX in MM cells with HP1γ KD treated with gradient concentration CPT for 4 h. d Left: immunofluorescence assay shows the level of γH2AX in WT and BR MM cells treated with CPT (2 μM) for 4 h. Right: quantification of γH2AX foci. At least 100 cells were counted, and n = 3 independent experiments. Data represent mean ± S.E.M., student’s t test. e Quantitative assessment of HR and NHEJ activities in HEK293T cells expressing vector control or HP1γ expressing plasmid via flow cytometry assay for the percentage of GFP+ cells among RFP+ cells. Quantitative data are shown as means ± s.e.m., student’s t test, and n = 3 (biologically independent experiments). f Co-IP assay shows bilateral interactions between endogenous HP1γ and MDC1. Input, 2% whole cell lysate. g Left: immunofluorescence assay demonstrating the HP1γ recruited to DNA damage regions in MDC1-KD CAG cells. Right: the graph represents the mean intensity of the HP1γ protein on the γH2AX track. Error bars represent S.E.M., n = 3 (biologically independent experiments), and differences relative to NT-Ctrl were calculated using student’s t test. Source data are provided as a Source data file.
Fig. 3 HP1γ facilitates homologous recombination of DNA repair. a Western blotting shows γH2AX and cleaved PARP in WT and BR MM cell treated with BTZ for 24 h. b Levels of γH2AX in WT and BR MM cells treated with camptothecin (CPT, 0–4 μM) for 24 h. c Western blotting shows γH2AX in MM cells with HP1γ KD treated with gradient concentration CPT for 4 h. d Left: immunofluorescence assay shows the level of γH2AX in WT and BR MM cells treated with CPT (2 μM) for 4 h. Right: quantification of γH2AX foci. At least 100 cells were counted, and n = 3 independent experiments. Data represent mean ± S.E.M., student’s t test. e Quantitative assessment of HR and NHEJ activities in HEK293T cells expressing vector control or HP1γ expressing plasmid via flow cytometry assay for the percentage of GFP+ cells among RFP+ cells. Quantitative data are shown as means ± s.e.m., student’s t test, and n = 3 (biologically independent experiments). f Co-IP assay shows bilateral interactions between endogenous HP1γ and MDC1. Input, 2% whole cell lysate. g Left: immunofluorescence assay demonstrating the HP1γ recruited to DNA damage regions in MDC1-KD CAG cells. Right: the graph represents the mean intensity of the HP1γ protein on the γH2AX track. Error bars represent S.E.M., n = 3 (biologically independent experiments), and differences relative to NT-Ctrl were calculated using student’s t test. Source data are provided as a Source data file.CC BY · PubMed Central
Fig. 4 Acetylation impairs nuclear condensation of HP1γ in vivo and vitro. a Upper: representative images and quantification of puncta count for endogenous foci of HP1γ in WT and BR MM.1 S and LP-1 cells. Error bars represent S.E.M., n = 3 (biologically independent experiments). Lower: quantification of puncta count is shown in images. b FRAP assay (upper) and kinetic recovery times (lower) for a HP1γ-GFP focus by 488 nm laser for 5″bleaching and 40″recovery in HEK293T cells transfected with HDAC1 or vector control (mean ± s.d.; n = 3 independent experiments). c Upper: Representative images for HP1γ foci in Vector and HDAC1 overexpression MM cells (n = 3). Lower: Quantification of puncta count is shown in images. d Visualization of turbidity associated with droplet formation in vitro for the GFP-vector control (Ctrl), (HP1γ-IDR1)-WT, -K5Q, K5R or -KallQ. e Turbidity (OD600) of WT, K5Q, K5R, and KallQ mutants of HP1γ-IDR1 in 200 mM NaCl and 10% PEG was measured (mean ± s.d.; n = 3 independent experiments). f FRAP assay for the recovery of fluorescence intensity of WT-, K5R- and K5Q-HP1γ-FL in HEK293T cells (mean ± s.d.; n = 3 independent experiments). g Microscopy images of GFP fusion proteins of WT-, K5Q- and K5R-HP1γ-FL before and after partial droplet photobleaching in vitro (mean ± s.d.; n = 3 independent experiments). h Visualization of turbidity associated with droplet formation in vitro for mock reaction and deacetylated HP1γ protein. i Turbidity (OD600) of mock reaction and deacetylated HP1γ protein in 200 mM NaCl and 10% PEG was measured (mean ± s.d.; n = 3 independent experiments). j Quantitative assessment of HR activity in the HEK293T cells expressing vector control or K5R-HP1γ via flow cytometry assay for the percentage of GFP+ cells among RFP+ cells (mean ± s.d.; n = 3 independent experiments). P values were determined by one-way ANOVA (b, i), two-way test (e, f, g) and Student’s t test (a, c, j). Source data are provided as a Source data file.
Fig. 4 Acetylation impairs nuclear condensation of HP1γ in vivo and vitro. a Upper: representative images and quantification of puncta count for endogenous foci of HP1γ in WT and BR MM.1 S and LP-1 cells. Error bars represent S.E.M., n = 3 (biologically independent experiments). Lower: quantification of puncta count is shown in images. b FRAP assay (upper) and kinetic recovery times (lower) for a HP1γ-GFP focus by 488 nm laser for 5″bleaching and 40″recovery in HEK293T cells transfected with HDAC1 or vector control (mean ± s.d.; n = 3 independent experiments). c Upper: Representative images for HP1γ foci in Vector and HDAC1 overexpression MM cells (n = 3). Lower: Quantification of puncta count is shown in images. d Visualization of turbidity associated with droplet formation in vitro for the GFP-vector control (Ctrl), (HP1γ-IDR1)-WT, -K5Q, K5R or -KallQ. e Turbidity (OD600) of WT, K5Q, K5R, and KallQ mutants of HP1γ-IDR1 in 200 mM NaCl and 10% PEG was measured (mean ± s.d.; n = 3 independent experiments). f FRAP assay for the recovery of fluorescence intensity of WT-, K5R- and K5Q-HP1γ-FL in HEK293T cells (mean ± s.d.; n = 3 independent experiments). g Microscopy images of GFP fusion proteins of WT-, K5Q- and K5R-HP1γ-FL before and after partial droplet photobleaching in vitro (mean ± s.d.; n = 3 independent experiments). h Visualization of turbidity associated with droplet formation in vitro for mock reaction and deacetylated HP1γ protein. i Turbidity (OD600) of mock reaction and deacetylated HP1γ protein in 200 mM NaCl and 10% PEG was measured (mean ± s.d.; n = 3 independent experiments). j Quantitative assessment of HR activity in the HEK293T cells expressing vector control or K5R-HP1γ via flow cytometry assay for the percentage of GFP+ cells among RFP+ cells (mean ± s.d.; n = 3 independent experiments). P values were determined by one-way ANOVA (b, i), two-way test (e, f, g) and Student’s t test (a, c, j). Source data are provided as a Source data file.CC BY · PubMed Central
Fig. 5 Interaction with MDC1-IDR enhances nuclear condensation of HP1γ. a FRAP assay for a MDC1-GFP focus (red circle) by 488 nm laser for 5″bleaching and 30″recovery in HEK293T cells (mean ± s.d.; n = 3 independent experiments). b Dispersion of GFP-MDC1 foci fluorescence in HEK293T cells before and after treatment with 3% 1,6-hexanediol (1,6-Hex) at different time. c Mapping MDC1 truncations including MDC1-N1, -N2, -N3, -M1, -M2, -C1 fragments and MDC-IDR1, -IDR2 and -IDR3. d GST-pulldown assay shows the direct interaction between purified HP1γ-GFP and GST-tagged-mCherry-MDC1-IDR1 or -IDR2 protein in vitro. e GST pull-down assay shows interactions between GST-HP1γ and truncations of MDC1. Input, 2% lysate. *, exact positions of different GFP-MDC1 truncation fusion proteins. f Visualization of turbidity associated with droplet formation in vitro for 50 μM MDC1-IDR1 and MDC1-IDR2 solutions (top) and liquid droplets visualized by DIC microscopy. g Microscopy images of mCherry fusion proteins of MDC1-IDR2 droplets before and after partial droplet photobleaching (mean ± s.d.; n = 3 independent experiments). h Representative images of droplet formation of mCherry-MDC1-IDR1 or mCherry-MDC1-IDR2 in the presence or absence of GFP or HP1γ-GFP. i Turbidity (OD600) of MDC1-IDR2 in the presence of MDC1-IDR2, GFP or HP1γ-GFP in 200 mM NaCl and 10% PEG was measured (mean ± s.d.; n = 3 independent experiments). P values were determined by two-way ANOVA test. j Confocal live-cell fluorescence microscopy of HEK293T cells co-transfected with HP1γ-mCherry and MDC1-GFP for 48 h. Source data are provided as a Source data file.
Fig. 5 Interaction with MDC1-IDR enhances nuclear condensation of HP1γ. a FRAP assay for a MDC1-GFP focus (red circle) by 488 nm laser for 5″bleaching and 30″recovery in HEK293T cells (mean ± s.d.; n = 3 independent experiments). b Dispersion of GFP-MDC1 foci fluorescence in HEK293T cells before and after treatment with 3% 1,6-hexanediol (1,6-Hex) at different time. c Mapping MDC1 truncations including MDC1-N1, -N2, -N3, -M1, -M2, -C1 fragments and MDC-IDR1, -IDR2 and -IDR3. d GST-pulldown assay shows the direct interaction between purified HP1γ-GFP and GST-tagged-mCherry-MDC1-IDR1 or -IDR2 protein in vitro. e GST pull-down assay shows interactions between GST-HP1γ and truncations of MDC1. Input, 2% lysate. *, exact positions of different GFP-MDC1 truncation fusion proteins. f Visualization of turbidity associated with droplet formation in vitro for 50 μM MDC1-IDR1 and MDC1-IDR2 solutions (top) and liquid droplets visualized by DIC microscopy. g Microscopy images of mCherry fusion proteins of MDC1-IDR2 droplets before and after partial droplet photobleaching (mean ± s.d.; n = 3 independent experiments). h Representative images of droplet formation of mCherry-MDC1-IDR1 or mCherry-MDC1-IDR2 in the presence or absence of GFP or HP1γ-GFP. i Turbidity (OD600) of MDC1-IDR2 in the presence of MDC1-IDR2, GFP or HP1γ-GFP in 200 mM NaCl and 10% PEG was measured (mean ± s.d.; n = 3 independent experiments). P values were determined by two-way ANOVA test. j Confocal live-cell fluorescence microscopy of HEK293T cells co-transfected with HP1γ-mCherry and MDC1-GFP for 48 h. Source data are provided as a Source data file.CC BY · PubMed Central
Fig. 6 HP1γ promotes expression of genes associated with MM drug resistance. a Volcano plot of differentially expressed genes analyzed from bulk RNA-sequencing in HP1γ overexpressing LP-1 cells. Blue, downregulated genes; red, upregulated genes; gray, statistically non-significance genes. b KEGG analysis for differentially expressed genes with a P < 0.05 using DAVID methods. c ChIP-seq profile of genes enriched by HP1γ in WT and BR LP-1 cells (n = 3 biologically independent experiments). d Pie chart to show percentages of HP1γ binding on gene locations. e Venn diagram shows the number of overlapped genes between HP1γ-ChIP and HP1γ overexpression RNA seq. QPCR shows expression of FOS, JUN and CD40 expressions in (f) the HP1γ overexpressing, (g) WT and BR MM.1 S and LP-1 cells, and (h) in 6 MM patients with disease progression before and after BTZ-based treatment (mean ± s.d.; n = 3 independent experiments). i Gene tracks showing representative ChIP-Seq profiles for the indicated proteins and histone marks at the FOS gene loci. ChIP-qPCR assay for the enrichment of HP1γ, H3K9me3 and H3K36me3 at gene loci of FOS in (j) LP-1 cells stably expressing vector or HP1γ, and (k) WT and BR LP-1 cells. Schematic representation of PCR primer design is provided. A, promoter region; B, intergenic region. Two-sided P values were determined by Student’s t test (f, g, j, k). Data indicate the mean ± SD, n = 3 independent experiments. Source data are provided as a Source data file.
Fig. 6 HP1γ promotes expression of genes associated with MM drug resistance. a Volcano plot of differentially expressed genes analyzed from bulk RNA-sequencing in HP1γ overexpressing LP-1 cells. Blue, downregulated genes; red, upregulated genes; gray, statistically non-significance genes. b KEGG analysis for differentially expressed genes with a P < 0.05 using DAVID methods. c ChIP-seq profile of genes enriched by HP1γ in WT and BR LP-1 cells (n = 3 biologically independent experiments). d Pie chart to show percentages of HP1γ binding on gene locations. e Venn diagram shows the number of overlapped genes between HP1γ-ChIP and HP1γ overexpression RNA seq. QPCR shows expression of FOS, JUN and CD40 expressions in (f) the HP1γ overexpressing, (g) WT and BR MM.1 S and LP-1 cells, and (h) in 6 MM patients with disease progression before and after BTZ-based treatment (mean ± s.d.; n = 3 independent experiments). i Gene tracks showing representative ChIP-Seq profiles for the indicated proteins and histone marks at the FOS gene loci. ChIP-qPCR assay for the enrichment of HP1γ, H3K9me3 and H3K36me3 at gene loci of FOS in (j) LP-1 cells stably expressing vector or HP1γ, and (k) WT and BR LP-1 cells. Schematic representation of PCR primer design is provided. A, promoter region; B, intergenic region. Two-sided P values were determined by Student’s t test (f, g, j, k). Data indicate the mean ± SD, n = 3 independent experiments. Source data are provided as a Source data file.CC BY · PubMed Central
Fig. 7 HP1γ facilities chromatin accessibility of genes governing drug sensitivity. a ATAC-seq profile of chromatin accessibility of genes in the Vector and HP1γ overexpressing LP-1 cells (n = 3 biologically independent experiments). b Genome-wide distribution of HP1γ accessibility regions in the Vector and HP1γ overexpressing LP-1 cells. c ATAC-seq profile of chromatin accessibility of genes in the WT and BR LP-1 cells (n = 3 biologically independent experiments). d Genome-wide distribution of HP1γ accessibility regions in the WT and BR LP-1 cells. e Gene tracks showing representative ATAC-Seq profiles at FOS, JUN and CD40 gene loci in LP-1 cells stably expressing vector or HP1γ OE, and (f) WT and BR LP-1 cells. g Gene tracks shows representative ATAC-Seq profiles at FOS, JUN and CD40 gene loci in 3 MM patients with disease progression before and after BTZ-based treatment. Source data are provided as a Source data file.
Fig. 7 HP1γ facilities chromatin accessibility of genes governing drug sensitivity. a ATAC-seq profile of chromatin accessibility of genes in the Vector and HP1γ overexpressing LP-1 cells (n = 3 biologically independent experiments). b Genome-wide distribution of HP1γ accessibility regions in the Vector and HP1γ overexpressing LP-1 cells. c ATAC-seq profile of chromatin accessibility of genes in the WT and BR LP-1 cells (n = 3 biologically independent experiments). d Genome-wide distribution of HP1γ accessibility regions in the WT and BR LP-1 cells. e Gene tracks showing representative ATAC-Seq profiles at FOS, JUN and CD40 gene loci in LP-1 cells stably expressing vector or HP1γ OE, and (f) WT and BR LP-1 cells. g Gene tracks shows representative ATAC-Seq profiles at FOS, JUN and CD40 gene loci in 3 MM patients with disease progression before and after BTZ-based treatment. Source data are provided as a Source data file.CC BY · PubMed Central
Fig. 8 HDAC1 inhibitor abolishes BTZ drug resistance and rehabilitates bone disruption in vitro and in vivo. a Quantification of apoptotic BR MM cells treated with BTZ (0–10 nM) and 100 nM Rom for 24 h (mean ± s.d.; n = 3 independent experiments). b Cleavage of PARP in BR MM cells treated with or without Rom, combined with increasing dosage of BTZ for 24 h. c Western blotting shows cleaved PARP in MM cell treated with increasing dosage of BTZ combined with LBH589 and Rom for 24 h. d Tumor growth of HP1γ KD or NT Ctrl BR MM.1 S cells (3×106 cells/mouse, n = 12/group) in NSG mice receiving BTZ (0.5 mg/kg) (mean ± s.d.). e Survival rate of mice at the time points of tumor diameter over 15 mm3. f Tumor growth of BR MM.1 S cells (3 × 106 cells/mouse, n = 12/group) in NSG mice receiving BTZ (0.5 mg/kg) or BTZ+Rom (1 mg/kg) (mean ± s.d.). g Survival rate of mice at the time points of tumor diameter over 15 mm3. h Immunofluorescence staining in tissues from xenograft of different mice groups. i Co-IP assay shows the ubiquitination and acetylation levels, and (j) protein levels of HP1γ in xenograft tissue of different treatment groups. #1–3: the mouse number selected randomly in BTZ and BTZ+Rom groups. k Relative expression of Fos, Jun and Cd40 in xenograft tissue of different treatment groups (mean ± s.d.; n = 3 independent experiments). l Left: representative microCT images of mouse femurs bearing BR MM.1 S cells and treated with BTZ or BTZ + Rom. Right: measurement of the percentage of bone volume to total volume (BV/TV) and trabecular number in the metaphyseal regions of the mice femurs (mean ± s.d.; n = 12 mice/group). m Levels of M protein secreted in PDX mouse tail vein blood after treatment with BTZ or BTZ + Rom (n = 3). Western blotting shows HP1γ-high and HP1γ-low level in the sorted CD138+ cell. P values were determined by Pearson’s coefficient and log-rank tests (m), one-side ANOVA (a, d–g), and Student’s t test (k, l). Source data are provided as a Source data file.
Fig. 8 HDAC1 inhibitor abolishes BTZ drug resistance and rehabilitates bone disruption in vitro and in vivo. a Quantification of apoptotic BR MM cells treated with BTZ (0–10 nM) and 100 nM Rom for 24 h (mean ± s.d.; n = 3 independent experiments). b Cleavage of PARP in BR MM cells treated with or without Rom, combined with increasing dosage of BTZ for 24 h. c Western blotting shows cleaved PARP in MM cell treated with increasing dosage of BTZ combined with LBH589 and Rom for 24 h. d Tumor growth of HP1γ KD or NT Ctrl BR MM.1 S cells (3×106 cells/mouse, n = 12/group) in NSG mice receiving BTZ (0.5 mg/kg) (mean ± s.d.). e Survival rate of mice at the time points of tumor diameter over 15 mm3. f Tumor growth of BR MM.1 S cells (3 × 106 cells/mouse, n = 12/group) in NSG mice receiving BTZ (0.5 mg/kg) or BTZ+Rom (1 mg/kg) (mean ± s.d.). g Survival rate of mice at the time points of tumor diameter over 15 mm3. h Immunofluorescence staining in tissues from xenograft of different mice groups. i Co-IP assay shows the ubiquitination and acetylation levels, and (j) protein levels of HP1γ in xenograft tissue of different treatment groups. #1–3: the mouse number selected randomly in BTZ and BTZ+Rom groups. k Relative expression of Fos, Jun and Cd40 in xenograft tissue of different treatment groups (mean ± s.d.; n = 3 independent experiments). l Left: representative microCT images of mouse femurs bearing BR MM.1 S cells and treated with BTZ or BTZ + Rom. Right: measurement of the percentage of bone volume to total volume (BV/TV) and trabecular number in the metaphyseal regions of the mice femurs (mean ± s.d.; n = 12 mice/group). m Levels of M protein secreted in PDX mouse tail vein blood after treatment with BTZ or BTZ + Rom (n = 3). Western blotting shows HP1γ-high and HP1γ-low level in the sorted CD138+ cell. P values were determined by Pearson’s coefficient and log-rank tests (m), one-side ANOVA (a, d–g), and Student’s t test (k, l). Source data are provided as a Source data file.CC BY · PubMed Central
Fig. 9 Proposed schematic diagram for mechanisms of HP1γ-MDC1-HDAC1 regulating axis in MM drug resistance. HP1γ-MDC1 complex recognizes the DSB sites and exerts the function of DNA repair, as well as how the nuclear condensation of HP1γ is regulated by deacetylation and facilitated by MDC1; HP1γ remodels histone methylation to facilitate accessibility of genes governing sensitivity to PIs; therefore, targeting HP1γ may be efficacious for overcoming drug resistance in MM patients.
Fig. 9 Proposed schematic diagram for mechanisms of HP1γ-MDC1-HDAC1 regulating axis in MM drug resistance. HP1γ-MDC1 complex recognizes the DSB sites and exerts the function of DNA repair, as well as how the nuclear condensation of HP1γ is regulated by deacetylation and facilitated by MDC1; HP1γ remodels histone methylation to facilitate accessibility of genes governing sensitivity to PIs; therefore, targeting HP1γ may be efficacious for overcoming drug resistance in MM patients.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

See all 27

Metadata

Authors
Li, X., Wang, S., Xie, Y., Jiang, H., Guo, J., Wang, Y., Peng, Z., Hu, M., Wang, M., Wang, J., Li, Q., Wang, Y., & Liu, Z.
Affiliations
  • Tianjin Medical University (CN)
  • Tianjin Medical University Cancer Institute and Hospital (CN)
Corresponding author
Liu, Zhiqiang
Venue
Nature Communications
Published
2023-03-09
Volume
14
Issue
1
Pages
1290-1290
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4323809200
Cited by
27
References
43
Citations by year
2026: 8 · 2025: 11 · 2024: 5 · 2023: 3
FWCI
5.56
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (82070221, 81870161, 81900215, 82270208)
Topics
  • Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Keywords
HP1γ, multiple myeloma, proteasome inhibitor resistance, bortezomib resistance, HDAC1, protein deacetylation, nuclear condensation, MDC1, DNA repair, chromatin accessibility, lysine acetylation, CD40, FOS, c-Jun
MeSH terms
Bortezomib, Antineoplastic Agents, Humans, Multiple Myeloma, Transcription Factors, Drug Resistance, Neoplasm, Cell Line, Tumor, Proteasome Endopeptidase Complex, Proteasome Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Deacetylation induced nuclear condensation of HP1γ promotes multiple myeloma drug resistance. https://app.cochat.ai/papers/10.1038/s41467-023-37013-x
The paper
Li, X., Wang, S., Xie, Y., Jiang, H., Guo, J., Wang, Y., Peng, Z., Hu, M., Wang, M., Wang, J., Li, Q., Wang, Y., & Liu, Z. (2023). Deacetylation induced nuclear condensation of HP1γ promotes multiple myeloma drug resistance. Nature Communications. https://doi.org/10.1038/s41467-023-37013-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.